Technology | November 16, 2006

Stent, Guide Wire Treat CAD in Patients at High Risk from CEA


Cordis Corp. has received approval from the FDA to market its PRECISE Nitinol Stent and ANGIOGUARD Emboli Capture guide wire. The system is used to treat carotid artery disease in patients at high risk for adverse events from carotid endarterectomy (CEA) — a surgical procedure for removing arterial plaque from the carotid artery.
The PRECISE with ANGIOGUARD is the only carotid system backed by a large, randomized clinical trial — the SAPPHIRE study — to support the potential benefits of carotid artery stenting (CAS) in patients who are ineligible, or considered high-risk, for carotid endarterectomy. The carotid system has been studied in over 3,000 patients across both SAPPHIRE and the Carotid Artery Stent Education System Post-Marketing Study and demonstrated low stroke rates in both.


Additional Content

News | Stents

Nov. 24, 2025 — InspireMD, Inc., developer of the CGuard Prime carotid stent system for the prevention of stroke ...

Home November 24, 2025
Home
News | Stents

Oct. 13, 2025 — Medtronic plc recently announced it has received U.S. Food and Drug Administration (FDA) labeling ...

Home October 13, 2025
Home
News | Stents

Oct. 16, 2024 — Sahajanand Medical Technologies (SMT) recently announced the publication of the COMPARE 60/80 HBR trial ...

Home October 16, 2024
Home
News | Stents

June 12, 2024 — Royal Philips, a global leader in health technology, announced the first implant of the Duo Venous Stent ...

Home June 12, 2024
Home
News | Stents

June 4, 2024 — A patient at HonorHealth Research Institute is one of the nation’s first — and the first in Arizona and ...

Home June 04, 2024
Home
Subscribe Now